Consequently, these findings suggest that lncRNA FOXD1-AS1 may serve as a potential biomarker for the effectiveness of 5-FU therapy and present an exciting avenue for therapeutic interventions in the context of PC. This evidence concerns the gene FOXD1 and pachyonychia congenita.